Zepto licence of this Mumbai facility cancelled over ‘poor hygiene and unsafe food storage conditions'
Zepto
's Dharavi facility after an inspection revealed multiple hygiene and food safety norms violations.
Tired of too many ads? go ad free now
According to an IANS report, the FDA's inspection was triggered by a tip-off from Minister of State for FDA Yogesh Kadam. The inspection uncovered fungal growth on some food items, storage near stagnant water, unclean and wet floors, and cold storage units that failed to maintain the necessary temperature. Officials also found expired food products that were not separated from fresh stock.
'The inspection at the Dharavi location revealed poor hygiene and unsafe food storage conditions,' said FDA officials.
Following these findings, Assistant Commissioner of Food, Anupamaa Balasaheb Patil, ordered the cancellation of the facility's licence under Section 32(3) of the Food Safety and Standards Act, 2006. The suspension will remain in place until Zepto resolves the issues and obtains clearance from the licensing authority.
More Zepto facilities under scrutiny
The fast-growing quick commerce firm is reportedly under regulatory scrutiny at several other locations in Mumbai.
Zepto's storage hubs in Bhiwandi, Bandra East, and Borivali have also come under inspection. While operations at Bhiwandi and Bandra East were not halted, notices were issued for rule violations.
In Borivali, the licence was briefly suspended but later reinstated after corrective steps were taken and approved by the FDA's appellate authority.
What Zepto said on licence suspension
The IANS report quotes a Zepto spokesperson who said:
'Maintaining the highest standards of food safety and hygiene is non-negotiable.
Tired of too many ads? go ad free now
We have already started an internal review and are working with authorities to fix the issues quickly.'
Zepto Cafe suspend services in Delhi, Chandigarh
Last month, Zepto paused its 10 minute food delivery service — Zepto Cafe in multiple cities across North India. According to a report by Economic Times, the company has temporarily suspended the services due to some supply chain issues. The report suggests that this decision of the company will impact 44 Zepto Cafe stores in the region.
The decision of the company to halt the service has affected around 700 gig workers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Problematic convenience leads to overspending in quick commerce
By Prateek Khanna and Ashish Gupta Q-commerce transforms the dynamics of the retail sector by changing consumer expectations by rapidly delivering products. This is an emerging sector in the retail business, as customers demand faster delivery, and companies seek scalable solutions. Technology breakthroughs, changing business models, and changing consumer behaviour contribute to the dramatic transformation of the retail industry. Traditional retail and e-commerce paradigms have been upended by the emergence of Q-commerce, compelling companies to reconsider their supply chains, logistics and customer engagement tactics. According to Statista (2025), the Quick Commerce market is expected to generate US$5.38 billion in revenue by 2025. Revenue is anticipated to grow at a compound annual growth rate (CAGR 2025-2030) of 15.54%, translating into a market volume of USD 265 billion by 2029. The number of users is expected to reach 65 million by 2030. User penetration is predicted to reach 2.7 % by the end of 2025 and is expected to hit 4.3% by 2030. Urbanisation, shifting lifestyles, transportation infrastructure, and demographic shifts all contribute to this growth. Q-commerce apps such as Zepto, Zomato, Blinkit, Dunzo, and Swiggy's Instamart have become extremely popular in the recent past because of their instant delivery . Initially serving as stores for groceries and other necessities, these apps have grown into full-fledged businesses that sell everything from electronic gadgets to the Fenni Sargi Sweets Box ( Karwa Chauth Special) and Pooja thali (Rakshabandhan and Diwali). However, it comes with hidden costs, most notably, the tendency to overspend without realising it. Although this convenience is revolutionary, it may have some drawbacks. The mental friction associated with spending, which usually slows impulsive decisions, is exacerbated by the fact that items are delivered faster than ever before. Quick commerce's behavioural, psychological, and economic effects are coming under closer scrutiny, as consumers frequently spend more money than they intend on items that may not always be necessary. Flash sales, free delivery offers, personalised recommendations, and gamified user interfaces are features of Q-commerce platforms that encourage impulsive purchasing. Instant Gratification Today, consumers increasingly seek immediate gratification. This need is met by Quick Commerce, which delivers goods in ten to 15 minutes quicker than most people can get to a local store or Kirana. Customers now prefer ordering even the smallest items, such as milk, bread and butter, biscuits, and chocolate, because of their convenience, resulting in ongoing and cumulative excessive spending. Reduced Purchase Friction Customers frequently go through a longer decision-making process when shopping. They might physically browse aisles, compare costs, or inspect the quality of products. The procedure was streamlined and digitised in Q-commerce. The barrier between desire and acquisition is almost completely removed with one-click purchases and saved payment methods, which leads to unforeseen spending, which eventually becomes overspending . Illusion of Micro/ Low-Cost Purchases Most orders on Q-commerce platforms are under ₹300, and customers frequently do not keep track of how frequently they make these small purchases. Individually, they seem reasonably priced, but when taken as a whole, they significantly strain their monthly budgets. When a lump-sum amount is not displayed until the end of the month, consumers frequently underestimate the total amount spent. Ms. Divya, a homemaker from Jaipur, acknowledged that she frequently adds items that she either has in her kitchen or will use later to reduce handling costs. Most Affected Demographics The groups most prone to excessive spending on Q-commerce are working parents, particularly mothers who are in charge of basic household expenses. Young professionals who have little free time and money. The availability of quick food and snacks frequently causes students to live away from home. Dr. Reetika Sehgal, an Assistant Professor at DIT University in Dehradun who is currently working in the Q-commerce area, shared some insights. She said that even elderly people and homemakers who do not have time constraints rely on quick delivery rather than going out themselves. These consumers are more inclined to convenience over pricing and make frequent micro purchases without considering the total financial impact. We are living in a world where everything we want is INSTANT, whether food, groceries, banking services, loan approval, or booking tickets and lists are endless. (The authors are based at Centre for Marketing Research and Communication, ICFAI Business School, Jaipur, India and at Faculty of Management, South Asian University, New Delhi (An International University established by SAARC Nations. Views expressed are personal.)
Time of India
2 days ago
- Time of India
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk's stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal challenges fuel concerns over the Danish drugmaker's grip on the global diabetes and obesity market. Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Tired of too many ads? Remove Ads Intensifying Competitive Pressures Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. Tired of too many ads? Remove Ads Leadership Transition Amid Turbulence Legal and Regulatory Headwinds Analysts Split: Crash or Correction? Novo Nordisk: Denmark's global pharma giant Tired of too many ads? Remove Ads Key Innovative Advances Bolster Long-Term Outlook Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. So, Is This a 'Nokia Moment'? Summary Snapshot Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Investor Takeaways Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. FAQs: Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded drugs and pharmacy compounding have reduced market share and investor confidence.
India.com
2 days ago
- India.com
Swiggy's Instamart beats Zepto in quick commerce, manages to race ahead on....
Swiggy Instamart vs Zepto Swiggy Instamart vs Blinkit vs Zepto: In a significant development in the quick-commerce industry which is being currently ruled by Swiggy Instamart, Blinkit and Zepto, Swiggy's quick commerce arm Instamart has witnessed a massive growth and has reclaimed the number two position from Zepto based on net merchandise value (NMV). As per a report by Moneycontrol, Zepto has fallen behind Swiggy's Instamart in terms of net merchandise value (NMV). Here are all the details you need to know about the recent development in the quick-commerce market and why it is a massive development for Swiggy. Who rules the quick commerce market? As per data release by the media report, Blinkit had an NMV of Rs 845 crore and Swiggy's Instamart and Zepto could only manage a NMV of Rs 405 crore and Rs 375 crore respectively in the week of August 4-11. For those unversed, Net Merchandise Value (NMV) is the actual value of goods sold after reducing for returns and cancellations from the total order value. Why it's big for Swiggy Instamart? Experts are praising the development for Swiggy as this is the first time in several months that Swiggy's Instamart has overtaken Zepto in market share terms, the report said. Therefore, it remains to be seen whether Zepto will be able to regain the lost spot from Swiggy Instamart or not. Why Zepto CEO accuses rival company's CFO of targeting them? In a development from May this year, Aadit Palicha, the CEO and Co-founder of quick delivery platform Zepto, had alleged that the chief financial officer (CFO) of a rival company is running a smear campaign against them over the past few days. Palicha said in a LinkedIn post that the spam campaign includes 'calling our investors to make wild allegations about us with no empirical evidence, giving out false numbers/Excel sheets on Zepto through sources known to journalists, and paying bots on social media to spread a negative narrative'. (With inputs from agencies)
